Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KH734
- Development stage
- Unknown
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
KH734 is a code name for an investigational drug being evaluated in clinical trials for the treatment of acute schizophrenia. The available information indicates that it is being compared to cariprazine hydrochloride capsules and aripiprazole tablets in a non-inferiority trial, suggesting that KH734 may be related to or a formulation of cariprazine, an atypical antipsychotic. The primary indication under investigation is acute schizophrenia. Detailed mechanism of action, molecular structure, and other pharmacological properties specific to KH734 are not publicly disclosed as of now[1][10].
- Other names
- KH734KH-734KH 734
Beyond the preview
Go deeper on KH734.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KH734.